A single intra-articular injection of a combinatorial gene therapy slows OA progression and reduces pain in small and large animal models, and identifies neuroinflammatory signatures for correction of disease progression and pain.
Biologic and regenerative interventions represent promising avenues for advancing cartilage repair and improving clinical outcomes in patients with osteoarthritis, and current evidence indicates that these therapies exert their effects through modulation of inflammatory pathways, enhancement of extracellular matrix syn...
Hai-Yuan Yue, Ahmad Alhaskawi, S. Ezzi et al.· Frontiers in Pharmacology· 0 citations
Osteoarthritis (OA) is a prevalent degenerative joint disease characterized by cartilage degradation, synovial inflammation, and subchondral bone changes, leading to chronic pain and functional impairment. Current treatments primarily alleviate symptoms but fail to halt disease progression or achieve cartilage regene...
Hao-Ran Zhu, Jin-Yang He, Yu-Jing Chen et al.· Stem Cell Research & The...· 0 citations
Rheumatoid arthritis (RA) is a systemic immune-mediated disease in which persistent synovial inflammation contributes not only to joint destruction but also to cardiovascular, pulmonary, metabolic, and other extra-articular complications. This review focuses specifically on the translational potential of emerging recep...
Roshanak Fekri Yazdi, Sze Ian Tan, Wei-Feng Bu et al.· Pharmacological Research· 0 citations
This work provides an integrated theoretical and translational roadmap for next‐generation disease‐modifying OA therapies, focusing on how renewable biomaterials, engineered exosomes, and their composite systems target and regulate the pathological network to restore joint homeostasis.
These findings support a neuroimmune model in which synovial immune heterogeneity influences treatment responsiveness, and concurrent immune remodeling via PRP and nociceptor inhibition via TRPV1 antagonism represents a promising strategy to achieve more reliable analgesia in OA.
Peng Liu, Jing-Wei Zhu, Yang Yang et al.· Frontiers in Pharmacology· 0 citations
Overall, curcumin represents a biologically plausible multitarget candidate for osteoarthritis, but larger, well-designed, standardized clinical trials incorporating structural and molecular endpoints are required to determine its therapeutic and disease-modifying potential.